Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» ONXX's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ONXX Guru Trades in

Q2 2013

ONXX Guru Trades in Q2 2013

Steven Cohen 496,428 sh (+361.03%)
Pioneer Investments 79,300 sh (+258.82%)
Mariko Gordon 7,138 sh (+72.04%)
Mariko Gordon 7,500 sh (unchged)
Columbia Wanger 1,127,000 sh (unchged)
Vanguard Health Care Fund 1,022,700 sh (unchged)
Stanley Druckenmiller Sold Out
Jim Simons Sold Out
RS Investment Management 18,400 sh (-7.07%)
» More
Q3 2013

ONXX Guru Trades in Q3 2013

Mario Gabelli 644,979 sh (New)
Prem Watsa 4,500 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
Vanguard Health Care Fund 1,022,700 sh (unchged)
Mariko Gordon Sold Out
Columbia Wanger Sold Out
Pioneer Investments Sold Out
RS Investment Management Sold Out
Steven Cohen Sold Out
» More
Q4 2013

ONXX Guru Trades in Q4 2013

Mario Gabelli Sold Out
Prem Watsa Sold Out
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Onyx Pharmaceuticals, Inc.

Mario Gabelli Comments on Onyx Pharmaceuticals Inc. - Jan 03, 2014

Onyx Pharmaceuticals Inc. (4.2%) (ONXX - $124.67 - NASDAQ) (ONXX) is a San Francisco based biotechnology company engaged in the development of cancer related drugs. On August 25, 2013, Amgen Inc. announced a $125.00 cash tender offer for the shares of Onyx. The offer came at the end of negotiations, which began in early June and were confirmed by the company on June 30. The tender, which commenced on September 3, is expected to close on October 1 of this year.


From Mario Gabelli's third quarter 2013 commentary.

Check out Mario Gabelli latest stock trades



Valuation & Return


Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:OX1.Germany,
Onyx Pharmaceuticals, Inc was incorporated in California in February 1992 and reincorporated in Delaware in May 1996. The Company is a biopharmaceutical company developing therapies that target the molecular mechanisms that cause cancer. Through the Company's internal research programs and in conjunction with its collaborators, the Company is applying its expertise to develop and commercialize innovative therapies that target the molecular mechanisms that cause cancer. The Company's commercially available products are Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and Kyprolis (carfilzomib) for Injection. Nexavar (sorafenib) tablets, is approved in multiple countries for unresectable liver cancer and advanced kidney cancer. Stivarga (regorafenib) tablets, a Bayer compound, is approved in the United States for the treatment of metastatic colorectal cancer (mCRC) and for the treatment of advanced gastrointestinal stromal tumors (GIST); and is under regulatory review for mCRC in the European Union and Japan and for the treatment of GIST in Japan. Kyprolis (carfilzomib) for Injection, is approved in the United States for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. . The Company is subject to federal, state and local laws and regulations governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain hazardous or potentially hazardous materials.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)